Aktienanalyse zu Sanofi SA (SNY)SNYSanofi SA

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sanofi SA (SNY) appears to be a good buy right now, with a current price of $41.60 and a forward P/E ratio of 8.59, indicating potential undervaluation compared to its earnings growth prospects. Additionally, insider buying has increased by 231.75% over the last quarter, suggesting strong confidence from those closest to the company. However, a key risk is the recent downgrade from Morgan Stanley, lowering the price target from $52 to $49, which reflects some skepticism about future catalysts.

3 analysts cover SNY: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 79.36.